Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature

Abstract: Anaplastic lymphoma kinase inhibitors (ALKi) are the standard of care for metastatic ALK-rearranged nonsmall cell lung cancer (NSCLC). Though most patients respond well to ALK, seldom there are instances where the disease progresses rapidly. Here, we present a case of a 41-years-old male diagnosed as NSCLC with ALK rearrangement. Despite being started on first- and second-generation ALK-targeted therapy, he had rapid disease progression ultimately succumbing to the disease within 3 months of diagnosis. We suspect that our patient has a variant of ALK, making him resistant to both first- and second-line targeted therapy. Subjecting such nonresponders to next-generation sequencing and identifying the variants might help to recognize a subset of patients among ALK+ NSCLC who will need intense monitoring and early institution of other therapies for a better outcome.

Show object

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature ; day:27 ; month:11 ; year:2023 ; Indian journal of medical & paediatric oncology ; (27.11.2023)

Contributors, Places and Time

• Contributor: Devaraj, Suma ; Panda, Soumya Surath ; Arun, Gourab ; Panda, Adya Kinkar ; Mohapatra, Debahuti ; Moharana, Lalatendu ; Kolluri, Spoorthy ; Kilaru, Sindhu ; Mohanty, Swati Sucharita ; Biswas, Ghanashyam

Further information

• DOI: 10.1055/s-0043-1776704
• URN: urn:nbn:de:101:1-2024011111185848523132
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.